Key facts
- HotHouse Therapeutics’s last known valuation is $9.0M (Dec 2025).
- It has raised $3.8M; the latest was Seed Round ($3.8M) in Dec 2025.
- Notable investors include Future Planet Capital, Cambridge Angels, UK Innovation & Science Seed Fund, Twin Path Ventures, John Innes Centre — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for HotHouse Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for HotHouse Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HotHouse Therapeutics
Operator of a biotechnology research firm intended to exploit the biochemical diversity of the plant kingdom to deliver new drugs and other high-value compounds. The company bio-engineers new high-potency adjuvants, alongside other projects to produce and improve other molecules with potential anti-inflammatory and anti-cancer activities, enabling the pharmaceutical industry to develop next-generation treatments with potentially enhanced efficacy and reduced side effects.
- Sector
- Healthcare
- HQ
- Norwich, United Kingdom
- Founded
- 2020
- Employees
- 10
- Website
- hothousetx.com/
- Ownership
- Privately Held (backing)
HotHouse Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HotHouse Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HotHouse Therapeutics in its N-PORT filings yet. We sweep new filings monthly.